NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $30.97 -1.56 (-4.80%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$30.03 -0.94 (-3.03%) As of 04/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harmony Biosciences Stock (NASDAQ:HRMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$30.75▼$32.2550-Day Range$30.97▼$39.5452-Week Range$28.14▼$41.61Volume630,253 shsAverage Volume556,453 shsMarket Capitalization$1.78 billionP/E Ratio14.68Dividend YieldN/APrice Target$53.33Consensus RatingBuy Company OverviewHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More… Remove Ads Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 88% of companies evaluated by MarketBeat, and ranked 102nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth27.98% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 14.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 14.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.25.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.45% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.45% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.97 News SentimentHarmony Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Harmony Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat Follows8 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,831,679.00 in company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Stock News HeadlinesHarmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of DirectorsApril 3 at 8:05 AM | businesswire.comHarmony Biosciences to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | msn.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 4, 2025 | Brownstone Research (Ad)Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to ConnectMarch 28, 2025 | markets.businessinsider.comMizuho Securities Sticks to Their Buy Rating for Harmony Biosciences Holdings (HRMY)March 28, 2025 | markets.businessinsider.comHarmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | businesswire.comHarmony Biosciences: A Compelling Risk-Reward OpportunityMarch 24, 2025 | seekingalpha.comHarmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakedaMarch 24, 2025 | markets.businessinsider.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $34.41 at the beginning of the year. Since then, HRMY shares have decreased by 10.0% and is now trading at $30.97. View the best growth stocks for 2025 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its quarterly earnings data on Tuesday, February, 25th. The company reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The company's revenue was up 19.5% on a year-over-year basis. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings2/25/2025Today4/03/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$53.33 High Stock Price Target$70.00 Low Stock Price Target$40.00 Potential Upside/Downside+72.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.51 Trailing P/E Ratio14.68 Forward P/E Ratio12.74 P/E Growth0.47Net Income$128.85 million Net Margins17.98% Pretax Margin25.71% Return on Equity23.16% Return on Assets14.24% Debt Debt-to-Equity Ratio0.28 Current Ratio3.24 Quick Ratio3.20 Sales & Book Value Annual Sales$714.73 million Price / Sales2.48 Cash Flow$2.31 per share Price / Cash Flow13.38 Book Value$7.97 per share Price / Book3.89Miscellaneous Outstanding Shares57,346,000Free Float39,465,000Market Cap$1.78 billion OptionableOptionable Beta0.82 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:HRMY) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.